Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
An experimental drug from Nektar Therapeutics was able to shrink tumors and reduce a cancer biomarker in women with advanced ovarian cancer in a mid-stage study.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
The U.S. Food and Drug Administration has approved a blood test to detect ovarian cancer and help physicians decide what kind of surgery should be done and by whom.